

For assistance, contact your pharmacy representative: _____ Phone: _____ (For providers only)

PLEASE CONSIDER SENDING YOUR PRESCRIPTION ELECTRONICALLY. ALL OF OUR PHARMACY LOCATIONS ACCEPT ELECTRONIC PRESCRIPTIONS.

Note: This form is intended for prescriber use only, if faxed, the fax must come from prescriber's office or hospital (may not be faxed by patient).



Orthopedic

Prescription/Pharmacy Intake Form

Central Pharmacy: _____
 Retail/Community Pharmacy Fax: _____ Pharmacy Phone: _____
Date Needed: _____ Treatment Setting: Patient's home Prescriber's office Walgreens

PATIENT INFORMATION

Patient name: _____ DOB: _____ Male Female
Address: _____
City: _____ State: _____ Zip code: _____
Phone # (Daytime): _____ Phone # (Evening): _____
E-mail Address: _____

Primary insurance (Please include copy of front and back of card): _____
ID #: _____ Policy/Group #: _____ Phone #: _____ Patient is eligible for Medicare
Name of Insured: _____ Employer: _____
Relationship to Patient: Self Other: _____ Prescription Card: Yes No Carrier: _____ Policy/Group #: _____
Secondary insurance (Please include copy of front and back of card): _____
ID #: _____ Policy/Group #: _____ Phone #: _____ Patient is eligible for Medicare
Name of Insured: _____ Employer: _____
Relationship to Patient: Self Other: _____ Prescription Card: Yes No Carrier: _____ Policy/Group #: _____

CLINICAL ASSESSMENT

Patient is new to therapy Therapy continuation Diagnosis Code (ICD-10): _____
Injection Site Bilateral Left Knee Right Knee
Clinical History Date of Diagnosis _____ Years with Disease _____
Injection Date _____ Therapy Stop Date _____
 Previous/Current Use of NSAIDs Previous/Current Use of Intra-articular Corticosteroids
Length of injection series _____ week(s) Frequency of injections per year _____
Clinical Notes _____
Allergies: _____

Medication	Form	Strength	Quantity	Directions/Frequency	Dose	Refills
<input type="checkbox"/> Durolane (sodium hyaluronate)	Pre-filled syringe	60 mg/3 mL				
<input type="checkbox"/> Euflexxa (sodium hyaluronate)	1 kit (3 syringes 2.0 mL each)	20 mg/2 mL				
<input type="checkbox"/> Gel-One (cross-linked hyaluronate)	Pre-filled syringe	30 mg/3 mL				
<input type="checkbox"/> Gelsyn-3 (sodium hyaluronate)	Pre-filled syringe	16.8 mg/2 mL				
<input type="checkbox"/> Genvisc 850 (sodium hyaluronate)	Pre-filled syringe	25 mg/2.5 mL				
<input type="checkbox"/> Hyalgan (sodium hyaluronate)	Pre-filled syringe	20 mg/2 mL				
<input type="checkbox"/> Monovisc (sodium hyaluronate)	Pre-filled syringe	88 mg/4 mL				
<input type="checkbox"/> Orthovisc (sodium hyaluronate)	Pre-filled syringe	30 mg/2 mL				
<input type="checkbox"/> Supartz FX (sodium hyaluronate)	Pre-filled syringe	25 mg/2.5 mL				
<input type="checkbox"/> Synvisc (hylan G-F 20)	1 kit (3 syringes 2.0 mL each)	16 mg/2 mL				
<input type="checkbox"/> Synvisc-One (hylan G-F 20)	Pre-filled syringe	48 mg/6 mL				
<input type="checkbox"/> Other:						

PRESCRIBER INFORMATION

Prescriber's name: _____ Practice/facility: _____
Address: _____ City: _____ State: _____ Zip code: _____
Office contact: _____ Phone: _____ Fax: _____
Email: _____ Best time to call: _____ Preferred method of contact: Email Phone Fax
State license #: _____ DEA #: _____ NPI #: _____ Medicaid UPIN #: _____

In order for a brand name product to be dispensed, the prescriber must handwrite "Brand Necessary" or "Brand Medically Necessary" or your state specific required language after their signature. I certify that the above therapy is medically necessary and that the information above is accurate to the best of my knowledge. Prescriber's signature required on one of the lines below.

Dispense as written

Substitution permitted

Date

The prescriber is to comply with his/her state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber. The document(s) accompanying this transmission may contain confidential health information that is legally protected. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless permitted or required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. Drug names are the property of their respective owners.